**FIRST INTERNATIONAL LIVE COURSE**

**ON DRUG-COATED BALLOON ANGIOPLASTY**

*from bench to an effective treatment*

## Atahotel Executive, Milano 30-31 maggio 2014

**Preliminary program**

**Friday May 30th**

|  |  |
| --- | --- |
| *8.30* | Welcome |
| *8.45* | **Course aims** |
| *9.00* | **Lecture**: how does paclitaxel work when applied to a dilatation balloon? |
| *9.15* | **ISR session** |
|  |  |
| *9.15* | update on DCB data for the treatment of BMS restenosis |
| *9.30* | update on DCB data for the treatment of DES restenosis |
| *9.45* | update with latest DCB trials |
| *10.00* | how do we judge the RIBS V results, and do we need more data for ISR management? |
| *10.15* | *discussion* |
|  |  |
| *10.45* | **I live case** |
|  |  |
| *11.30* | *discussion* |
|  |  |
| *11.45* | **Lecture**: DCB years 2006-2014: what have we learned from our mistakes? |
| *12.00* | **Native vessels session**: |
|  |  |
| *12.00* | DCB followed by stent implantation |
| *12.15* | DCB in bifurcation lesions |
| *12.30* | DCB in small vessels |
| *12:45* | DCB angioplasty: lessons from real world experiences |
| *13.00* | *discussion* |
| *13.15* | *lunch* |
|  |  |
| *14.00* | **interesting cases/recent abstracts** |
|  |  |
| *15.00* | **II live case** |
|  |  |
| *15.45* | *discussion* |
|  |  |
| *16.00* | **Lecture**: what type of prosthesis should I use after DCB (in case I need one!) |
| *16.20* | *coffee break* |
| *17:00* | **Controversy session** |
|  |  |
| *17.00* | DCB in BTK are dead! |
| *17.15* | DCB in BTK are well alive! |
| *17.30* | *discussion* |
| *17:45* | **Lecture**: what type of scientific evidence do we need, to increase DCB use? |
| *18.15* | **Round table about DCB-PCI reimbursement** |
|  | Pharmacoeconomic evaluation of DCB-PCI |
|  | Should the German reimbursement be an example for other european countries? |
|  | *discussion with authorities* |
| *19.15* | *end of day 1 sessions and dinner* |

**Saturday May 31st**

|  |  |
| --- | --- |
| *8.30* | **Peripheral session** |
|  |  |
| *8.30* | DCB for femoral artery PTA: what else? Direct and indirect comparison with stents |
| *8.45* | DCB for BTK-PTA, experience from my first 2000 cases |
| *9.00* | The erectyle disfunction dilemma: is DCB a possible answer? |
| *9.15* | Intracerebral or dialysis shunts with DCB |
| *9.30* | *discussion* |
|  |  |
| *09.45* | *coffee break* |
| *10.15* | **Lecture**: how is the DCB of the future? |
| *10.30* | **Pharmacology session** |
|  |  |
| *10.30* | Is there a real advantage over stents regarding DAPT duration? Lessons from animal models. |
| *10.45* | Is there a real advantage over stents regarding DAPT duration? Clinical data. |
| *11.00* | DCB in the context of new oral anticoagulants. |
|  |  |
| *11.15* | **DCB Consensus Group** |
| *11.15* | which consensus in DCB-angioplasty in 2014? |
| *11.30* | the DCB Consensus Group: what we aim to? |
|  |  |
| *11.45* | **Didactical session** |
|  |  |
| *11.45* | How should I perform my DCB-angioplasty? |
| *12.00* | The role of FFR, IVUS and OCT |
| *12.15* | DCB promotes positive remodeling |
| *12.30* | *discussion* |
|  |  |
| *12.45* | **End of the Course – key messages & the trials of the future** |